54 results on '"Saha, Vaskar"'
Search Results
2. Relapsed Acute Lymphoblastic Leukemia.
- Author
-
Sidhu, Jasmeet, Gogoi, Manash Pratim, Krishnan, Shekhar, and Saha, Vaskar
- Abstract
Outcomes for children with acute lymphoblastic leukemia (ALL) have improved worldwide to >85%. For those who relapse, outcomes have remained static at ~50% making relapsed acute lymphoblastic leukemia one of the leading causes of death in childhood cancers. Those relapsing within 18 mo in the bone marrow have a particularly dismal outcome. The mainstay of treatment is chemotherapy, local radiotherapy with or without hematopoietic stem cell transplantation (HSCT). Improved biological understanding of mechanisms of relapse and drug resistance, use of innovative strategies to identify the most effective and least toxic treatment regimens and global partnerships are needed to improve outcomes in these patients. Over the last decade, new therapeutic options and strategies have been developed for relapsed ALL including immunotherapies and cellular therapies. It is imperative to understand how and when to use these newer approaches in relapsed ALL. Increasingly, integrated precision oncology strategies are being used to individualize treatment of patients with relapsed ALL, especially in patients with poor response disease. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
3. The role of relative advantage for development of sequencing‐based diagnostics for pediatric cancer in low‐ and middle‐income countries.
- Author
-
Berger, Anissa, Rennie, Stuart, Aijaz, Javeria, Johnson, Liza‐Marie, Antillon, Federico, Roberts, Megan C., Chitsike, Inam, Kambugu, Joyce, Saha, Vaskar, Bhakta, Nickhill, Davis, Arlene M., and Alexander, Thomas B.
- Subjects
MIDDLE-income countries ,CHILDHOOD cancer ,HIGH-income countries ,DIAGNOSIS methods - Abstract
Efforts to address limitations in cancer diagnostics in low‐ and middle‐income countries should follow an approach that avoids two extremes: unproductive attempts to require implementation of high‐income country gold standards or acquiescence to the diagnostic status quo. The relative advantage of implementing new diagnostic tests (including sequencing‐based approaches) should be determined through comparison to local standards of care, with context‐specific clinical utility determined using locally available therapeutic options. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
4. Hybrid Email and Outpatient Clinics to Optimize Maintenance Therapy in Acute Lymphoblastic Leukemia.
- Author
-
Mungle, Tushar, Mahadevan, Ananya, Das, Parag, Mehta, Amit K., Gogoi, Manash P., Jana, Bishwaranjan, Ghara, Niharendu, Ghosh, Debjani, Saha, Vaskar, and Krishnan, Shekhar
- Published
- 2024
- Full Text
- View/download PDF
5. Maintenance Treatment in Acute Lymphoblastic Leukemia: A Clinical Primer.
- Author
-
Krishnan, Shekhar, Mahadevan, Ananya, Mungle, Tushar, Gogoi, Manash Pratim, and Saha, Vaskar
- Abstract
Cure rates in pediatric acute lymphoblastic leukemia (ALL) currently approach 90% in the developed world. Treatment involves 6-8 mo of intensive multi-drug chemotherapy followed by 24 mo of maintenance treatment (ALL-MT). The cornerstone of ALL-MT is the daily administration of oral 6-mercaptopurine (6MP), a purine analogue. 6MP is combined with weekly oral methotrexate (MTX), an antifolate drug, to augment therapeutic activity. Some protocols include additional chemotherapy drugs (such as vincristine and corticosteroids) during MT. The objective of ALL-MT is to ensure uninterrupted treatment at the highest tolerated doses of 6MP and MTX. This requires periodic adjustments of 6MP and MTX doses throughout treatment. Tolerance is determined through regular clinical assessments and careful monitoring of blood counts. Tolerated drug doses vary widely among patients, influenced by genetic and non-genetic factors, and require individualized dosing. Suboptimal treatment intensity in ALL-MT is associated with inferior outcomes and results from failure to treat at highest tolerated drug doses and/or interruptions in treatment due to non-adherence or toxicity. Management of MT thus requires close supervision to ensure treatment adherence, periodic drug dose modifications, and treatment to tolerance, while minimizing treatment interruptions due to toxicity. The review highlights these challenges and discusses approaches and strategies for the management of MT, focusing on the Indian context. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
6. Development of EPAT: An assessment tool for pediatric hematology/oncology training programs.
- Author
-
Moreira, Daniel C., Metzger, Monika L., Antillón‐Klussmann, Federico, González‐Ramella, Oscar, Gao, Yijin, Bazzeh, Faiha, Middlekauff, Janet, Fox Irwin, Leeanna, Gonzalez, Miriam L., Chantada, Guillermo, Barr, Ronald D., Garrington, Timothy, Hastings, Caroline, Kutluk, Tezer, Saab, Raya, Khan, Muhammad Saghir, Saha, Vaskar, Rodríguez‐Galindo, Carlos, and Friedrich, Paola
- Subjects
PEDIATRIC hematology ,MEDICAL care ,ONCOLOGY ,TEST validity ,PEDIATRIC oncology - Abstract
Purpose: In the absence of a standardized tool to assess the quality of pediatric hematology/oncology training programs, the Education Program Assessment Tool (EPAT) was conceptualized as a user‐friendly and adaptable tool to evaluate and identify areas of opportunity, pinpoint needed modifications, and monitor progress for training programs around the world. Methods: The development of EPAT consisted of three main phases: operationalization, consensus, and piloting. After each phase, the tool was iteratively modified based on feedback to improve its relevance, usability, and clarity. Results: The operationalization process led to the development of 10 domains with associated assessment questions. The two‐step consensus phase included an internal consensus phase to validate the domains and a subsequent external consensus phase to refine the domains and overall function of the tool. EPAT domains for programmatic evaluation are hospital infrastructure, patient care, education infrastructure, program basics, clinical exposure, theory, research, evaluation, educational culture, and graduate impact. EPAT was piloted in five training programs in five countries, representing diverse medical training and patient care contexts for proper validation of the tool. Face validity was confirmed by a correlation between the perceived and calculated scores for each domain (r = 0.78, p <.0001). Conclusions: EPAT was developed following a systematic approach, ultimately leading to a relevant tool to evaluate the different core elements of pediatric hematology/oncology training programs across the world. With EPAT, programs will have a tool to quantitatively evaluate their training, allowing for benchmarking with centers at the local, regional, and international level. The Education Program Assessment Tool (EPAT) is an adaptable tool to evaluate and identify areas of opportunity, pinpoint needed modifications, and monitor progress for pediatric hematology/oncology fellowship programs around the world. This tool was developed following a systematic approach, ultimately leading to a relevant tool to quantitatively evaluate programs and their training, allowing for benchmarking with centers at the local, regional, and international levels. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
7. Characteristics and outcomes of gallbladder cancer patients at the Tata Medical Center, Kolkata 2017–2019.
- Author
-
Dutta, Anindita, Mungle, Tushar, Chowdhury, Nandita, Banerjee, Pritha, Gehani, Anisha, Sen, Saugata, Mallath, Mohandas, Roy, Paromita, Krishnan, Shekhar, Ganguly, Sandip, Banerjee, Sudeep, Roy, Manas, and Saha, Vaskar
- Subjects
CANCER prognosis ,GALLBLADDER cancer ,ELECTRONIC health records ,MEDICAL centers ,SURVIVAL rate ,OVERALL survival - Abstract
Background: The north and north‐eastern regions of India have among the highest incidence of gallbladder cancer (GBC) in the world. We report the clinicopathological charateristics and outcome of GBC patients in India. Methods: Electronic medical records of patients diagnosed with GBC at Tata Medical Center, Kolkata between 2017 and 2019 were analyzed. Results: There were 698 cases of confirmed GBC with a median age of 58 (IQR: 50–65) years and female:male ratio of 1.96. At presentation, 91% (496/544) had stage III/IV disease and 30% (189/640) had incidental GBC. The 2‐year overall survival (OS) was 100% (95% CI: 100–100); 61% (95% CI: 45–83); 30% (95% CI: 21–43); and 9% (95% CI: 6–13) for stages I–IV, respectively (p = <0.0001). For all patients, the 2‐year OS in patients who had a radical cholecystectomy followed by adjuvant therapy (N = 36) was 50% (95% CI: 39–64), compared to 29% (95% CI: 22–38) for those who had a simple cholecystectomy and/or chemotherapy (N = 265) and 9% (95% CI: 6–14) in patients who were palliated (N = 107) (p = <0.0001). Conclusion: The combined surgical/chemotherapy approach for patients with stage II GBC showed the best outcomes. Early detection of GBC remains problematic with the majority of patients presenting with stage III–IV and who have a median survival of 9.1 months. Our data suggests that the tumor is chemoresponsive and multi‐center collaborative clinical trials to identify alternative therapies are urgently required. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
8. Comparative treatment costs of risk‐stratified therapy for childhood acute lymphoblastic leukemia in India.
- Author
-
Mungle, Tushar, Das, Nandana, Pal, Saikat, Gogoi, Manash Pratim, Das, Parag, Ghara, Niharendu, Ghosh, Debjani, Arora, Ramandeep Singh, Bhakta, Nickhill, Saha, Vaskar, and Krishnan, Shekhar
- Subjects
LYMPHOBLASTIC leukemia ,ACUTE leukemia ,ELECTRONIC health records ,ELECTRONIC billing ,COST effectiveness - Abstract
Background: To evaluate the treatment cost and cost effectiveness of a risk‐stratified therapy to treat pediatric acute lymphoblastic leukemia (ALL) in India. Methods: The cost of total treatment duration was calculated for a retrospective cohort of ALL children treated at a tertiary care facility. Children were risk stratified into standard (SR), intermediate (IR) and high (HR) for B‐cell precursor ALL, and T‐ALL. Cost of therapy was obtained from the hospital electronic billing systems and details of outpatient (OP) and inpatient (IP) from electronic medical records. Cost effectiveness was calculated in disability‐adjusted life years. Results: One hundred and forty five patients, SR (50), IR (36), HR (39), and T‐ALL (20) were analyzed. Median cost of the entire treatment for SR, IR, HR, and T‐ALL was found to be $3900, $5500, $7400, and $8700, respectively, with chemotherapy contributing to 25%–35% of total cost. Out‐patient costs were significantly lower for SR (p < 0.0001). OP costs were higher than in‐patient costs for SR and IR, while in‐patient costs were higher in T‐ALL. Costs for non‐therapy admissions were significantly higher in HR and T‐ALL (p < 0.0001), representing over 50% of costs of in‐patient therapy. HR and T‐ALL also had longer durations of non‐therapy admissions. Based on WHO‐CHOICE guidelines, the risk‐stratified approach was very cost effective for all categories of patients. Conclusions: Risk‐stratified approach to treat childhood ALL is very cost‐effective for all categories in our setting. The cost for SR and IR patients is significantly reduced through decreased IP admissions for both, chemotherapy and non‐chemotherapy reasons. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
9. Detection of constitutional mismatch repair deficiency in children and adolescents with acute lymphoblastic leukemia.
- Author
-
Gallon, Richard, Phelps, Rachel, Betts, Leigh, Hayes, Christine, Masic, Dino, Irving, Julie A. E., McAnulty, Ciaron, Saha, Vaskar, Vora, Ajay, Wimmer, Katharina, Motwani, Jayashree, Macartney, Christine, Burn, John, Jackson, Michael S., Moorman, Anthony V., and Santibanez-Koref, Mauro
- Subjects
LYMPHOBLASTIC leukemia ,ACUTE leukemia ,TEENAGERS ,DNA mismatch repair ,HEREDITARY nonpolyposis colorectal cancer - Abstract
A previous literature review found at least 4/9 (>=44.4%) CMMRD-associated ALL were T-ALL [[1]], and 8/88 (9.1%, 95% CI: 0.4-17.1%) childhood T-LBL patients were diagnosed with CMMRD in a consecutive series between 2007 and 2020 [[15]], suggesting an association of CMMRD with T cell lineage malignancies. For example, PCR-fragment length analysis has been shown to be insensitive to MSH6 deficiency in ALL relapse samples [[3]], and detected increased MSI in only 27% of CMMRD haematological malignancies and in 0% of non-neoplastic CMMRD tissues [[9]]. Here, 1/17 (5.9%, 95% CI: 0.2-28.7%) ALL patients with SMN had CMMRD, which is similar to the 14/189 (7.4%, 95% CI: 4.1-12.1%) pediatric non-Hodgkin lymphoma patients with SMN who had CMMRD in another recent study [[16]]. Constitutional mismatch repair deficiency (CMMRD, MIM #276300) is a rare, recessive pediatric and adolescent cancer syndrome, caused by pathogenic variants in a mismatch repair (MMR) gene: I MLH1 i , I MSH2 i , I MSH6 i , or I PMS2 i . [Extracted from the article]
- Published
- 2023
- Full Text
- View/download PDF
10. Activity and toxicity of intramuscular 1000 iu/m2 polyethylene glycol‐E. coliL‐asparaginase in the UKALL 2003 and UKALL 2011 clinical trials.
- Author
-
Sidhu, Jasmeet, Masurekar, Ashish Narayan, Gogoi, Manash Pratim, Fong, Caroline, Ioannou, Tasos, Lodhi, Taha, Parker, Catriona, Liu, Jizhong, Kirkwood, Amy A., Moorman, Anthony V., Das, Kiranmoy, Goulden, Nicholas J., Vora, Ajay, Saha, Vaskar, and Krishnan, Shekhar
- Subjects
DRUG monitoring ,CLINICAL trials ,POLYETHYLENE ,LYMPHOBLASTIC leukemia ,ACUTE leukemia - Abstract
Summary: In successive UK clinical trials (UKALL 2003, UKALL 2011) for paediatric acute lymphoblastic leukaemia (ALL), polyethylene glycol‐conjugated E. coli L‐asparaginase (PEG‐EcASNase) 1000 iu/m2 was administered intramuscularly with risk‐stratified treatment. In induction, patients received two PEG‐EcASNase doses, 14 days apart. Post‐induction, non‐high‐risk patients (Regimens A, B) received 1–2 doses in delayed intensification (DI) while high‐risk Regimen C patients received 6–10 PEG‐EcASNase doses, including two in DI. Trial substudies monitored asparaginase (ASNase) activity, ASNase‐related toxicity and ASNase‐associated antibodies (total, 1112 patients). Median (interquartile range) trough plasma ASNase activity (14 ± 2 days post dose) following first and second induction doses and first DI dose was respectively 217 iu/l (144–307 iu/l), 265 iu/l (165–401 iu/l) and 292 iu/l (194–386 iu/l); 15% (138/910) samples showed subthreshold ASNase activity (<100 iu/l) at any trough time point. Older age was associated with lower (regression coefficient −9.5; p < 0.0001) and DI time point with higher ASNase activity (regression coefficient 29.9; p < 0.0001). Clinical hypersensitivity was observed in 3.8% (UKALL 2003) and 6% (UKALL 2011) of patients, and in 90% or more in Regimen C. A 7% (10/149) silent inactivation rate was observed in UKALL 2003. PEG‐EcASNase schedule in UKALL paediatric trials is associated with low toxicity but wide interpatient variability. Therapeutic drug monitoring potentially permits optimisation through individualised asparaginase dosing. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
11. Protocol for ICiCLe-ALL-14 (InPOG-ALL-15-01): a prospective, risk stratified, randomised, multicentre, open label, controlled therapeutic trial for newly diagnosed childhood acute lymphoblastic leukaemia in India.
- Author
-
Das, Nandana, Banavali, Shripad, Bakhshi, Sameer, Trehan, Amita, Radhakrishnan, Venkatraman, Seth, Rachna, Arora, Brijesh, Narula, Gaurav, Sinha, Subir, Roy, Prakriti, Gogoi, Manash Pratim, Chatterjee, Sayan, Abraham, Bindhu, Das, Parag, Saha, Vaskar, and Krishnan, Shekhar
- Subjects
LYMPHOBLASTIC leukemia ,ACUTE leukemia ,LEUCOCYTES ,DATABASE management ,BASILIXIMAB ,FINANCIAL stress ,CHILDHOOD cancer - Abstract
Background: In the west, survival following treatment of childhood acute lymphoblastic leukaemia (ALL) approaches 90%. Outcomes in India do not exceed 70%. To address this disparity, the Indian Collaborative Childhood Leukaemia group (ICiCLe) developed in 2013 a contemporary treatment protocol for uniform risk-stratified management of first presentation ALL based on cytogenetics and minimal residual disease levels (MRD). A multicentre randomised clinical trial opened in 2016 (ICiCLe-ALL-14) and examines the benefit of randomised interventions to decrease toxicity and improve outcomes.Methods: Patients 1-18 years with newly diagnosed ALL are categorised into four risk groups based on presentation features, tumour genetics and treatment response. Standard risk includes young (< 10 years) B cell precursor ALL (BCP-ALL) patients with low presentation leucocyte count (< 50 × 109/L) and no high-risk features. Intermediate risk includes BCP-ALL patients with no high-risk features but are older and have high presentation leucocyte counts and/or bulky disease. High risk includes BCP-ALL patients with any high-risk feature, including high-risk genetics, central nervous system leukaemia, poor prednisolone response at treatment day 8 and high MRD (≥ 0·01%) at the end of induction. Patients with T-lineage ALL constitute the fourth risk group. All patients receive four intensive treatment blocks (induction, consolidation, interim maintenance, delayed intensification) followed by 96 weeks of maintenance. Treatment intensity varies by risk group. Clinical data management is based on a web-based remote data capture system. The first randomisation examines the toxicity impact of a shorter induction schedule of prednisolone (3 vs 5 weeks) in young non-high-risk BCP-ALL. The second randomisation examines the survival benefit of substituting doxorubicin with mitoxantrone in delayed intensification for all patients. Primary outcome measures include event-free survival (overall, by risk groups), sepsis rates in induction (first randomisation) and event-free survival rates following second randomisation.Discussion: ICiCLe-ALL-14 is the first multicentre randomised childhood cancer clinical trial in India. The pre-trial phase allowed standardisation of risk-stratification diagnostics and established the feasibility of collaborative practice, uniform treatment, patient enrolment and data capture. Pre-trial observations confirm the impact of risk-stratified therapy in reducing treatment-related deaths and costs. Uniform practice across centres allows patients to access care locally, potentially decreasing financial hardship and dislocation.Trial Registration: Clinical Trials Registry-India (CTRI) CTRI/2015/12/006434 . Registered on 11 December 2015. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
12. Unsatisfactory quality of E. coli asparaginase biogenerics in India: Implications for clinical outcomes in acute lymphoblastic leukaemia.
- Author
-
Sidhu, Jasmeet, Gogoi, Manash Pratim, Agarwal, Praveen, Mukherjee, Tathagata, Saha, Debparna, Bose, Priyanka, Roy, Prakriti, Phadke, Yogesh, Sonawane, Bhatu, Paul, Pritha, Saha, Vaskar, and Krishnan, Shekhar
- Published
- 2021
- Full Text
- View/download PDF
13. Effect of Blinatumomab vs Chemotherapy on Event-Free Survival Among Children With High-risk First-Relapse B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial.
- Author
-
Locatelli, Franco, Zugmaier, Gerhard, Rizzari, Carmelo, Morris, Joan D., Gruhn, Bernd, Klingebiel, Thomas, Parasole, Rosanna, Linderkamp, Christin, Flotho, Christian, Petit, Arnaud, Micalizzi, Concetta, Mergen, Noemi, Mohammad, Abeera, Kormany, William N., Eckert, Cornelia, Möricke, Anja, Sartor, Mary, Hrusak, Ondrej, Peters, Christina, and Saha, Vaskar
- Subjects
LYMPHOBLASTIC leukemia in children ,LYMPHOBLASTIC leukemia treatment ,STEM cell transplantation ,CANCER relapse ,CANCER chemotherapy ,THERAPEUTIC use of immunoglobulins ,THERAPEUTIC use of antineoplastic agents ,SURVIVAL ,RESEARCH ,IMMUNOGLOBULINS ,LYMPHOBLASTIC leukemia ,RESEARCH methodology ,PROGNOSIS ,ANTINEOPLASTIC agents ,MEDICAL cooperation ,EVALUATION research ,DISEASE relapse ,COMPARATIVE studies ,RANDOMIZED controlled trials ,LYMPHOCYTIC leukemia ,DRUG therapy ,KAPLAN-Meier estimator ,HEMATOPOIETIC stem cell transplantation ,COMBINED modality therapy ,STATISTICAL sampling ,IMMUNOTHERAPY ,LONGITUDINAL method - Abstract
Importance: Blinatumomab is a CD3/CD19-directed bispecific T-cell engager molecule with efficacy in children with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL).Objective: To evaluate event-free survival in children with high-risk first-relapse B-ALL after a third consolidation course with blinatumomab vs consolidation chemotherapy before allogeneic hematopoietic stem cell transplant.Design, Setting, and Participants: In this randomized phase 3 clinical trial, patients were enrolled November 2015 to July 2019 (data cutoff, July 17, 2019). Investigators at 47 centers in 13 countries enrolled children older than 28 days and younger than 18 years with high-risk first-relapse B-ALL in morphologic complete remission (M1 marrow, <5% blasts) or with M2 marrow (blasts ≥5% and <25%) at randomization.Intervention: Patients were randomized to receive 1 cycle of blinatumomab (n = 54; 15 μg/m2/d for 4 weeks, continuous intravenous infusion) or chemotherapy (n = 54) for the third consolidation.Main Outcomes and Measures: The primary end point was event-free survival (events: relapse, death, second malignancy, or failure to achieve complete remission). The key secondary efficacy end point was overall survival. Other secondary end points included minimal residual disease remission and incidence of adverse events.Results: A total of 108 patients were randomized (median age, 5.0 years [interquartile range {IQR}, 4.0-10.5]; 51.9% girls; 97.2% M1 marrow) and all patients were included in the analysis. Enrollment was terminated early for benefit of blinatumomab in accordance with a prespecified stopping rule. After a median of 22.4 months of follow-up (IQR, 8.1-34.2), the incidence of events in the blinatumomab vs consolidation chemotherapy groups was 31% vs 57% (log-rank P < .001; hazard ratio [HR], 0.33 [95% CI, 0.18-0.61]). Deaths occurred in 8 patients (14.8%) in the blinatumomab group and 16 (29.6%) in the consolidation chemotherapy group. The overall survival HR was 0.43 (95% CI, 0.18-1.01). Minimal residual disease remission was observed in more patients in the blinatumomab vs consolidation chemotherapy group (90% [44/49] vs 54% [26/48]; difference, 35.6% [95% CI, 15.6%-52.5%]). No fatal adverse events were reported. In the blinatumomab vs consolidation chemotherapy group, the incidence of serious adverse events was 24.1% vs 43.1%, respectively, and the incidence of adverse events greater than or equal to grade 3 was 57.4% vs 82.4%. Adverse events leading to treatment discontinuation were reported in 2 patients in the blinatumomab group.Conclusions and Relevance: Among children with high-risk first-relapse B-ALL, treatment with 1 cycle of blinatumomab compared with standard intensive multidrug chemotherapy before allogeneic hematopoietic stem cell transplant resulted in an improved event-free survival at a median of 22.4 months of follow-up.Trial Registration: ClinicalTrials.gov Identifier: NCT02393859. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
14. The cost-effectiveness of pegaspargase versus native asparaginase for first-line treatment of acute lymphoblastic leukaemia: a UK-based cost-utility analysis.
- Author
-
Hu, Xingdi, Wildman, Kingsley P., Basu, Subham, Lin, Peggy L., Rowntree, Clare, and Saha, Vaskar
- Subjects
LYMPHOBLASTIC leukemia ,ASPARAGINASE ,COST effectiveness ,QUALITY-adjusted life years ,MEDICAL technology - Abstract
Background: L-asparaginase is a key component of treatment for patients with acute lymphoblastic leukaemia (ALL) in the UK. Commonly used forms of asparaginase are native E. coli-derived asparaginase (native asparaginase) and pegaspargase in first-line combination therapy, and native Erwinia chrysanthemi-derived asparaginase (Erwinia asparaginase) as second-line treatment. The objective of this study was to evaluate the cost-effectiveness of pegaspargase versus native asparaginase in first-line combination therapy for patients with newly diagnosed ALL. A combined decision tree and health-state transition Markov cost-effectiveness model was developed to assess the relative costs and health outcomes of pegaspargase versus native asparaginase in the UK setting. Results: In base case analyses, first-line pegaspargase (followed by Erwinia asparaginase in cases of hypersensitivity) dominated first-line native asparaginase followed by Erwinia asparaginase; i.e. resulted in lower costs and more quality-adjusted life year gain. The favourable hypersensitivity rates and administration profile of pegaspargase led to lifetime cost savings of £4741 versus native asparaginase. Pegaspargase remained cost-effective versus all treatment strategies in all scenario analyses, including use of the 2500 IU/m
2 dose, recommended for patients ≤21 years of age. Conclusions: Pegaspargase, as part of multi-drug chemotherapy, is a cost-effective option for the treatment of newly diagnosed ALL. Based on this study, The National Institute for Health and Care Excellence Technology Appraisal Committee concluded that it could recommend pegaspargase as a cost-effective use of National Health Service resources in England & Wales for treating ALL in children, young people and adults with untreated, newly diagnosed disease. Trial registration: UKALL 2011, EudraCT number 2010-020924-22; UKALL 2003, EudraCT number 2007-004013-34; UKALL14, EudraCT number 2009-012717-22. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
15. Efficacy and safety of a bortezomib and reduced‐intensity cytarabine‐based protocol, TMC ALLR1, for relapsed childhood ALL in India.
- Author
-
Roy, Prakriti, Islam, Rubina, Saha, Debparna, Gogoi, Manash, Kumar Mishra, Deepak, Arora, Neeraj, Parihar, Mayur, Krishnan, Shekhar, and Saha, Vaskar
- Subjects
CHILDREN ,CONFIDENCE intervals - Abstract
Summary: The feasibility of bortezomib (BZB) in induction and reduced cytarabine doses in intensification was evaluated in children with relapsed acute lymphoblastic leukaemia (rALL) at a single centre in India. Of 55 children with rALL, 23 received supportive care and 7 refused treatment, with a median survival of 2 (interquartile range 1–6) months. Twenty‐two (88%) of 25 children who were treated achieved second remission and 9 (69%) of 13 had end‐of‐induction minimal residual disease of <10−4. The lower cytarabine dose was associated with decreased hospitalisation. One‐year event‐free and overall survival for the treated group was 74·7% (95% confidence interval 52–88) and 79·6% (58–91) respectively. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
16. Surveillance and caregiver vaccination prevent varicella outbreaks in a residential care facility for children with cancer.
- Author
-
Bhattacharyya, Arpita, Das, Anirban, Dalvi‐Mitra, Sonal, Goel, Gaurav, Bhattacharya, Sanjay, Chowdhury, Shampa, and Saha, Vaskar
- Published
- 2022
- Full Text
- View/download PDF
17. Differential regulation of cell death pathways by the microenvironment correlates with chemoresistance and survival in leukaemia.
- Author
-
Qattan, Malak Yahia, Bakker, Emyr Yosef, Rajendran, Ramkumar, Chen, Daphne Wei-Chen, Saha, Vaskar, Liu, Jizhong, Zeef, Leo, Schwartz, Jean-Marc, Mutti, Luciano, Demonacos, Constantinos, and Krstic-Demonacos, Marija
- Subjects
CELL death ,LEUKEMIA treatment ,TUMOR microenvironment ,SURVIVAL analysis (Biometry) ,DEXAMETHASONE - Abstract
Glucocorticoids (GCs) and topoisomerase II inhibitors are used to treat acute lymphoblastic leukaemia (ALL) as they induce death in lymphoid cells through the glucocorticoid receptor (GR) and p53 respectively. Mechanisms underlying ALL cell death and the contribution of the bone marrow microenvironment to drug response/resistance remain unclear. The role of the microenvironment and the identification of chemoresistance determinants were studied by transcriptomic analysis in ALL cells treated with Dexamethasone (Dex), and Etoposide (Etop) grown in the presence or absence of bone marrow conditioned media (CM). The necroptotic (RIPK1) and the apoptotic (caspase-8/3) markers were downregulated by CM, whereas the inhibitory effects of chemotherapy on the autophagy marker Beclin-1 (BECN1) were reduced suggesting CM exerts cytoprotective effects. GCs upregulated the RIPK1 ubiquitinating factor BIRC3 (cIAP2), in GC-sensitive (CEM-C7-14) but not in resistant (CEM-C1-15) cells. In addition, CM selectively affected GR phosphorylation in a site and cell-specific manner. GR is recruited to RIPK1, BECN1 and BIRC3 promoters in the sensitive but not in the resistant cells with phosphorylated GR forms being generally less recruited in the presence of hormone. FACS analysis and caspase-8 assays demonstrated that CM promoted a pro-survival trend. High molecular weight proteins reacting with the RIPK1 antibody were modified upon incubation with the BIRC3 inhibitor AT406 in CEM-C7-14 cells suggesting that they represent ubiquitinated forms of RIPK1. Our data suggest that there is a correlation between microenvironment-induced ALL proliferation and altered response to chemotherapy. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
18. Mixed-phenotypic acute leukemia series from tertiary care center.
- Author
-
Pawar, Ravikiran N., Banerjee, Sambhunath, Bramha, Subhajit, Krishnan, Shekhar, Bhattacharya, Arpita, Saha, Vaskar, Chakrapani, Anupam, Bhave, Saurabh, Chandy, Mammen, Nair, Reena, Parihar, Mayur, Arora, Neeraj, and Mishra, D. K.
- Published
- 2017
- Full Text
- View/download PDF
19. Outcome of Central Nervous System Relapses In Childhood Acute Lymphoblastic Leukaemia – Prospective Open Cohort Analyses of the ALLR3 Trial.
- Author
-
Masurekar, Ashish Narayan, Parker, Catriona A., Shanyinde, Milensu, Moorman, Anthony V., Hancock, Jeremy P., Sutton, Rosemary, Ancliff, Philip J., Morgan, Mary, Goulden, Nicholas J., Fraser, Chris, Hoogerbrugge, Peter M., Revesz, Tamas, Darbyshire, Philip J., Krishnan, Shekhar, Love, Sharon B., and Saha, Vaskar
- Subjects
CENTRAL nervous system ,LYMPHOBLASTIC leukemia in children ,IDARUBICIN ,MITOXANTRONE ,PROGENITOR cells ,CANCER relapse - Abstract
: The outcomes of Central Nervous System (CNS) relapses in children with acute lymphoblastic leukaemia (ALL) treated in the ALL R3 trial, between January 2003 and March 2011 were analysed. Patients were risk stratified, to receive a matched donor allogeneic transplant or fractionated cranial irradiation with continued treatment for two years. A randomisation of Idarubicin with Mitoxantrone closed in December 2007 in favour of Mitoxantrone. The estimated 3-year progression free survival for combined and isolated CNS disease were 40.6% (25·1, 55·6) and 38.0% (26.2, 49.7) respectively. Univariate analysis showed a significantly better survival for age <10 years, progenitor-B cell disease, good-risk cytogenetics and those receiving Mitoxantrone. Adjusting for these variables (age, time to relapse, cytogenetics, treatment drug and gender) a multivariate analysis, showed a poorer outcome for those with combined CNS relapse (HR 2·64, 95% CI 1·32, 5·31, p = 0·006 for OS). ALL R3 showed an improvement in outcome for CNS relapses treated with Mitoxantrone compared to Idarubicin; a potential benefit for matched donor transplant for those with very early and early isolated-CNS relapses. Trial Registration: Controlled-Trials.com [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
20. Reply to: Comment on: Unsatisfactory quality of E. coli asparaginase biogenerics in India—Implications for clinical outcomes in acute lymphoblastic leukaemia.
- Author
-
Sidhu, Jasmeet, Saha, Vaskar, and Krishnan, Shekhar
- Published
- 2022
- Full Text
- View/download PDF
21. Complex genomic alterations and gene expression in acute lymphoblastic leukemia with intrachromosomal amplification of chromosome 21.
- Author
-
Strefford, Jon C., van Delft, Frederik W., Robinson, Hazel M., Worley, Helen, Yiannikouris, Olga, Selzer, Rebecca, Richmond, Todd, Hann, Ian, Bellotti, Tony, Raghavan, Manoj, Young, Bryan D., Saha, Vaskar, and Harrison, Christine J.
- Subjects
LYMPHOBLASTIC leukemia ,CHROMOSOMES ,GENOMICS ,GENE expression ,COMPARATIVE genomic hybridization - Abstract
We have previously identified a unique subtype of acute lymphoblastic leukemia (ALL) associated with a poor outcome and characterized by intrachromosomal amplification of chromosome 21 including the RUNX1 gene (iAMP21). In this study, array-based comparative genomic hybridization (aCGH) (n = 0) detected a common region of amplification (CRA) between 33.192 and 39.796 Mb and a common region of deletion (CRD) between 43.7 and 47 Mb in 100% and 70% of iAMP21 patients, respectively. High-resolution genotypic analysis (n = 3) identified allelic imbalances in the CRA. Supervised gene expression analysis showed a distinct signature for eight patients with iAMP21, with 10% of overexpressed genes located within the CRA. The mean expression of these genes was significantly higher in iAMP21 when compared to other ALL samples (n = 45). Although genomic copy number correlated with overall gene expression levels within areas of loss or gain, there was considerable individual variation. A unique subset of differentially expressed genes, outside the CRA and CRD, were identified when gene expression signatures of iAMP21 were compared to ALL samples with ETV6-RUNXI fusion (n = 21) or high hyperdiploidy with additional chromosomes 21 (n = 23). From this analysis, LGMN was shown to be overexpressed in patients with iAMP21 (P = 0.0012). Genomic and expression data has further characterized this ALL subtype, demonstrating high levels of 21q instability in these patients leading to proposals for mechanisms underlying this clinical phenotype and plausible alternative treatments. [ABSTRACT FROM AUTHOR]
- Published
- 2006
- Full Text
- View/download PDF
22. Philadelphia positive acute lymphoblastic leukaemia of childhood.
- Author
-
Jones, Louise K. and Saha, Vaskar
- Subjects
LYMPHOBLASTIC leukemia ,LEUKEMIA in children ,STEM cell transplantation ,CELL transplantation ,TRANSPLANTATION of organs, tissues, etc. ,HEMATOLOGY - Abstract
On current chemotherapeutic regimens, children with Philadelphia positive acute lymphoblastic leukaemia show a heterogeneous response to treatment. A few respond quickly to treatment and achieve long-term remission. Some fail to achieve remission after induction and the majority respond slowly to treatment. Relapse on treatment is common and remission is sustained in a proportion of cases only after allogeneic stem cell transplantation (allo-SCT). The use of imatinib along with conventional cytoreductive therapy, prior to allo-SCT appears to be the most promising strategy. The future lies in the molecular evaluation of response to treatment and combination targeted chemotherapy. [ABSTRACT FROM AUTHOR]
- Published
- 2005
- Full Text
- View/download PDF
23. QUALIFIED PREDICTIONS FOR MICROARRAY AND PROTEOMICS PATTERN DIAGNOSTICS WITH CONFIDENCE MACHINES.
- Author
-
BELLOTTI, TONY, ZHIYUAN LUO, GAMMERMAN, ALEX, VAN DELFT, FREDERICK W., and SAHA, VASKAR
- Subjects
PROTEOMICS ,MOLECULAR biology ,PROTEINS ,BIOCHEMISTRY ,BIOPHYSICS ,BIOMOLECULES - Abstract
We focus on the problem of prediction with confidence and describe a recently developed learning algorithm called transductive confidence machine for making qualified region predictions. Its main advantage, in comparison with other classifiers, is that it is well-calibrated, with number of prediction errors strictly controlled by a given predefined confidence level. We apply the transductive confidence machine to the problems of acute leukaemia and ovarian cancer prediction using microarray and proteomics pattern diagnostics, respectively. We demonstrate that the algorithm performs well, yielding well-calibrated and informative predictions whilst maintaining a high level of accuracy. [ABSTRACT FROM AUTHOR]
- Published
- 2005
- Full Text
- View/download PDF
24. Prospective gene expression analysis accurately subtypes acute leukaemia in children and establishes a commonality between hyperdiploidy and t(12;21) in acute lymphoblastic leukaemia.
- Author
-
van Delft, Frederik W., Bellotti, Tony, Zhiyuan Luo, Jones, Louise K., Patel, Naina, Yiannikouris, Olga, Hill, Alex S., Hubank, Mike, Kempski, Helena, Fletcher, Danielle, Chaplin, Tracy, Foot, Nicola, Young, Bryan D., Hann, Ian M., Gammerman, Alex, and Saha, Vaskar
- Subjects
GENE expression ,GENETIC regulation ,LEUKEMIA in children ,PEDIATRIC hematology ,MOLECULAR diagnosis ,TELOMERES ,MATHEMATICAL models - Abstract
We have prospectively analysed and correlated the gene expression profiles of children presenting with acute leukaemia to the Royal London and Great Ormond Street Hospitals with morphological diagnosis, immunophenotype and karyotype. Total RNA extracted from freshly sorted blast cells was obtained from 84 lymphoblastic [acute lymphoblastic leukaemia (ALL)], 20 myeloid [acute myeloid leukaemia (AML)] and three unclassified acute leukaemias and hybridised to the high density Affymetrix U133A oligonucleotide array. Analysis of variance and significance analysis of microarrays was used to identify discriminatory genes. A novel 50-gene set accurately identified all patients with ALL and AML and predicted for a diagnosis of AML in three patients with unclassified acute leukaemia. A unique gene set was derived for each of eight subtypes of acute leukaemia within our data set. A common profile for children with ALL with an ETV6– RUNX1 fusion, amplification or deletion of ETV6, amplification of RUNX1 or hyperdiploidy with an additional chromosome 21 was identified. This suggests that these rearrangements share a commonality in biological pathways that maintains the leukaemic state. The gene TERF2 was most highly expressed in this group of patients. Our analyses demonstrate that not only is microarray analysis the single most effective tool for the diagnosis of acute leukaemias of childhood but it has the ability to identify unique biological pathways. To further evaluate its prognostic value it needs to be incorporated into the routine diagnostic analysis for large-scale clinical trials in childhood acute leukaemias. [ABSTRACT FROM AUTHOR]
- Published
- 2005
- Full Text
- View/download PDF
25. Outcome after first relapse in childhood acute lymphoblastic leukaemia – lessons from the United Kingdom R2 trial.
- Author
-
Roy, Anindita, Cargill, Anna, Love, S., Moorman, Anthony V., Stoneham, Sara, Lim, Anita, Darbyshire, Phil J., Lancaster, Donna, Hann, Ian, Eden, Tim, and Saha, Vaskar
- Subjects
LYMPHOBLASTIC leukemia in children ,LEUKEMIA in children ,DISEASE relapse ,DISEASE risk factors ,PEDIATRIC hematology ,HEMATOLOGY - Abstract
A retrospective analysis of children with first relapse of acute lymphoblastic leukaemia (ALL), treated on the UKALL R2 protocol at four different hospitals, between June 1995 and December 2002 was performed. Of the 150 children 139 (93%) achieved a second complete remission. The overall survival (OS) and event-free survival (EFS) for the whole group was 56% and 47% respectively. The duration of first complete remission and immunophenotype, but not sites of relapse, were predictive for survival. Using the Berlin–Frankfürt–Münster risk stratification for relapsed ALL, the OS and EFS for standard, intermediate (IR) and high risk (HR) groups were 92% and 92%, 64% and 51%, and 14% and 15%, respectively; P < 0·0001 for both OS and EFS. In the IR group, those with a very early isolated central nervous system relapse also had a significantly worse outcome ( P = 0·0001). Given the poor outcome of a second relapse, clear strategies are required to identify those in the IR group who will most benefit from stem cell transplantation (SCT). A higher proportion (16%) of induction failures in the HR group suggest the need for novel agents during this phase of treatment, but SCT was associated with a lower relapse rate and better outcome than those treated with chemotherapy alone. [ABSTRACT FROM AUTHOR]
- Published
- 2005
- Full Text
- View/download PDF
26. LISA: a web-based decision-support system for trial management of childhood acute lymphoblastic leukaemia.
- Author
-
Bury, Jonathan, Hurt, Chris, Roy, Anindita, Cheesman, Louise, Bradburn, Mike, Cross, Simon, Fox, John, and Saha, Vaskar
- Subjects
DECISION support systems ,LYMPHOBLASTIC leukemia in children ,LEUKEMIA in children ,DRUG therapy ,MEDICATION errors ,BLOOD - Abstract
Continuation chemotherapy is a key component of the treatment of childhood acute lymphoblastic leukaemia. During this treatment phase, weekly dose adjustments are carried out based on current and historical full blood counts (FBCs). The dose decision pathway is complex and suboptimal therapy may result if information on FBC results is not readily available and/or the prescriber is inexperienced. A web-based decision-support system (Leukaemia Intervention Scheduling and Advice,‘LISA’) was designed to facilitate access to FBC information across geographical locations and to assist with dosage adjustments. A balanced-block crossover analysis was performed to evaluate the system. Thirty-six clinicians with varying degrees of experience were each asked to decide on appropriate oral chemotherapy dosages for eight simulated cases: four using LISA and four without. LISA significantly reduced the number of erroneous prescriptions (zero of 144 with LISA vs. 54 of 144 without; P < 0·0001) without affecting the number of times subjects deliberately overrode the protocol (seven of 144 times using LISA and six of 144 without). Using LISA reduced the time taken by novices to reach a decision for each case but increased the time taken by experts. Thirty-five of 36 subjects said they would be likely to use the system if it were available. A system like LISA is likely to be acceptable to clinicians, and has the potential to increase protocol compliance and decrease prescribing errors while allowing clinicians to override the protocol in specific cases where sound reasons exist for doing so. [ABSTRACT FROM AUTHOR]
- Published
- 2005
- Full Text
- View/download PDF
27. Early response to induction is predictive of survival in childhood Philadelphia chromosome positive acute lymphoblastic leukaemia: results of the Medical Research Council ALL 97 trial.
- Author
-
Roy, Anindita, Bradburn, Mike, Moorman, Anthony V., Burrett, Julie, Love, Sharon, Kinsey, Sally E., Mitchell, Chris, Vora, Ajay, Eden, Tim, Lilleyman, John S., Hann, Ian, and Saha, Vaskar
- Subjects
LYMPHOBLASTIC leukemia ,CLINICAL trials ,PATIENTS ,CHROMOSOMES ,THERAPEUTICS ,BONE marrow transplantation - Abstract
We report on the outcome of children with Philadelphia positive acute lymphoblastic leukaemia (Ph+ ALL) treated on the UK Medical Research Council (MRC) trial for childhood ALL, MRC ALL 97, between January 1997 and June 2002. Forty-two (2·3%) patients were Ph+. Nineteen (45%) had<25% blasts in bone marrow (BM) within the first 2 weeks of treatment and were defined as a good response group (GRG), the others as a poor response group (PRG). Thirty-six (86%) achieved first complete remission (CR1) at the end of induction, of which 28 underwent BM transplantation (BMT). The median follow-up was 42 months (range, 21–84). The 3-year event-free survival (EFS; 52%, 95% CI, 36–66%) was a considerable improvement on the previous MRC UKALL XI trial (27%). EFS for the GRG and PRG were 68% (43–84%) and 39% (18–59%), respectively (P = 0·03); presenting white cell count<50 × 10
9 /l (P = 0·02) was predictive for overall survival. Changes in the MRC ALL97 trial within the study period resulted in some Ph+ ALL receiving daunorubicin and either prednisolone or dexamethasone during induction. Though the use of daunorubicin during induction was not a prospective study question, EFS was significantly better for those whose induction included this drug (P = 0·02). Steroid randomization was not stratified for Ph+ ALL patients and was not predictive for EFS. BMT in CR1 appeared to reduce the risk of a subsequent BM relapse. These results show significant improvement on previous MRC trials; future therapeutic strategies should include early intensive therapy and BMT in CR1. [ABSTRACT FROM AUTHOR]- Published
- 2005
- Full Text
- View/download PDF
28. Expression profile of wild-type ETV6 in childhood acute leukaemia.
- Author
-
Patel, Naina, Goff, Lindsey K., Clark, Taane, Ford, Anthony M., Foot, Nicola, Lillington, Debra, Hing, Sandra, Pritchard-Jones, Kathy, Jones, Louise K., and Saha, Vaskar
- Subjects
MYELOID leukemia ,CANCER patients ,LEUKEMIA - Abstract
Summary. Comparative expression analysis of wild-type ETV6 in the disease state showed an absence of expression in ETV6–CBFA2 acute lymphoblastic leukaemia (ALL) when compared with non-ETV6–CBFA2 ALL and acute myeloid leukaemia. Fluorescent in-situ hybridization and loss of heterozygosity studies showed that 73% of the ETV6–CBFA2 samples had a fully or partially deleted second ETV6 allele, explaining the lack of wild-type expression in these patients. Although the second ETV6 allele was identified in the remaining patients, no ETV6 expression was detected. These observations support the hypothesis that loss of ETV6 expression is a critical secondary event for leukaemogenesis in ETV6–CBFA2 ALL. [ABSTRACT FROM AUTHOR]
- Published
- 2003
- Full Text
- View/download PDF
29. Chromatin Modification, Leukaemia and Implications for Therapy.
- Author
-
Jones, Louise K. and Saha, Vaskar
- Subjects
CHROMATIN ,LEUKEMIA ,THERAPEUTICS - Abstract
Summarizes the mechanisms in place for chromatin remodelling and leukemia. Enzymes involved in protein modification; Information on how chromosomal translocations in acute leukemia disrupt chromatin remodelling pathways; Examples of novel therapeutic agents capable of restoring chromatin structure.
- Published
- 2002
- Full Text
- View/download PDF
30. Evidence that continued remission in patients treated for acute leukaemia is dependent upon autologous natural killer cells.
- Author
-
Lowdell, Mark W, Craston, Rose, Samuel, David, Wood, Marion E, O'Neill, Elena, Saha, Vaskar, and Prentice, H. Grant
- Subjects
CELL-mediated cytotoxicity ,LEUKEMIA ,IMMUNOTHERAPY - Abstract
Summary. Although it has been known for more than 40 years that allogeneic immune responses cure leukaemias after bone marrow transplantation, autologous leukaemia-specific immunity remains controversial and its impact upon survival has not been established. Here we have tested 25 patients with de novo acute leukaemias, while in remission at completion of their anti-leukaemia therapy, for evidence of autologous cytolytic immunity to their leukaemic cells taken and cryopreserved at disease presentation. We have measured this degree of cell-mediated cytotoxicity in vitro and termed it ‘leukaemia cytolytic activity’ (LCA). Patients whose disease ultimately relapsed had significantly lower LCA than those who remained in remission beyond 2 years (P < 0·001); the absence of LCA when in remission predicted subsequent relapse within 2 years with a sensitivity of 100% and specificity of 77%. LCA was mediated in vitro by CD56
+ /CD8α+ /CD3– natural killer cells. We propose that it is this immune response, rather than the chemotherapy per se , which is responsible for continued remission and that measurement of LCA in patients at completion of therapy may be used as an indicator of risk of subsequent relapse. Patients lacking this response will require further treatment, either with an allogeneic donor transplant or an alternative immunotherapeutic strategy. [ABSTRACT FROM AUTHOR]- Published
- 2002
- Full Text
- View/download PDF
31. Cytogenetic and molecular evidence of marrow involvement in extramedullary acute myeloid leukaemia.
- Author
-
Lillington, Debra M., Jaju, Rina J., Shankar, A. G., Neat, Michael, Kearney, Lyndal, Young, Bryan D., and Saha, Vaskar
- Subjects
CYTOGENETICS ,BONE marrow ,MYELOID leukemia genetics ,HEMATOLOGY ,CYTOLOGY - Abstract
A diagnosis of granulocytic sarcoma was made in a 2-year-old child based on the detection of myelomonocytic blasts in tissue obtained from a subcutaneous nodule with no evidence of concomitant disease in the bone marrow. The child responded to systemic chemotherapy and is in remission 3 years later. An identical clone with an in frame fusion of the MLL and AF10 genes was identified from both tissue and bone marrow samples. The generation of an in frame MLL–AF10 fusion requires complex intra- and interchromosomal exchanges between chromosomes 10 and 11. In this case, an intrachromosomal rearrangement of chromosome 5 was also observed. This case illustrates the presence of systemic disease in extramedullary leukaemia, its response to systemic rather than topical therapy and suggests that the events leading to chromosomal translocations in leukaemia may be part of a generalized intracellular event. [ABSTRACT FROM AUTHOR]
- Published
- 2000
- Full Text
- View/download PDF
32. Translocations, fusion genes, and acute leukemia.
- Author
-
Saha, Vaskar, Young, Bryan D., and Freemont, Paul S.
- Published
- 1998
- Full Text
- View/download PDF
33. The cloning, mapping and expression of a novel gene, BRL, related to the AF10 leukaemia gene.
- Author
-
McCullagh, Paul, Chaplin, Tracy, Meerabux, Joanne, Grenzelias, Demetrios, Lillington, Debra, Poulsom, Richard, Gregorini, Armando, Saha, Vaskar, and Young, Bryan D
- Subjects
ONCOGENES ,LEUKEMIA genetics ,GENE expression ,CLONING ,GENE mapping - Abstract
The MLL gene is reciprocally translocated with one of a number of different partner genes in a proportion of human acute leukaemias. The precise mechanism of oncogenic transformation is unclear since most of the partner genes encode unrelated proteins. However, two partner genes, AF10 and AF17 are related through the presence of a cysteine rich region and a leucine zipper. The identification of other proteins with these structures will aid our understanding of their role in normal and leukaemic cells. We report the cloning of a novel human gene (BRL) which encodes a protein containing a cysteine rich region related to that of AF10 and AF17 and is overall most closely related to the previously known protein BR140. BRL maps to chromosome 22q13 and shows high levels of expression in testis and several cell lines. The deduced protein sequence also contains a bromodomain, four potential LXXLL motifs and four predicted nuclear localization signals. A monoclonal antibody raised to a BRL peptide sequence confirmed its widespread expression as a 120 Kd protein and demonstrated localization to the nucleus within spermatocytes. [ABSTRACT FROM AUTHOR]
- Published
- 1999
- Full Text
- View/download PDF
34. Once daily ceftriaxone and gentamicin for the treatment of febrile neutropenia.
- Author
-
Tomlinson, Richard J., Ronghe, Milind, Goodbourne, Colin, Price, Christine, Lilleyman, John S., Das, Satya, Saha, Vaskar, Tomlinson, R J, Ronghe, M, Goodbourne, C, Price, C, Lilleyman, J S, Das, S, and Saha, V
- Abstract
Aims: To evaluate the pharmacokinetics of once daily (OD) gentamicin and its effectiveness as part of an OD regimen for the empirical treatment of febrile neutropenia in children with cancer.Subjects: 59 children aged 6 months to 16 years (mean (SD) 5.7 (4) years) with febrile neutropenia (neutrophil count < 0.5 x 10(9)/l) after chemotherapy.Methods: Over one year, 113 febrile neutropenic episodes were treated empirically with an OD antibiotic regimen of ceftriaxone (80 mg/kg; maximum 4 g) and gentamicin (7 mg/kg; infused over 60 minutes, no maximum). The patients were assessed after 48 hours.Results: 86 of the 113 episodes settled with the first line antibiotic regimen. In 29 episodes, blood cultures identified a causative bacterial pathogen; for 17 of these, the first line antibiotic regimen was adequate; in four episodes, although the episode settled, ceftriaxone was replaced by a more appropriate antibiotic and OD gentamicin was continued; in the remaining eight episodes, a glycopeptide antibiotic was deemed necessary. There was no failure of treatment in organisms sensitive to gentamicin, including Pseudomonas aeruginosa. In 27 episodes (24%), resolution was obtained by the empirical introduction of a second line regimen of ceftazidime and a glycopeptide antibiotic, and/or amphotericin. Gentamicin concentrations were measured in 110 episodes and they were all below the 24 hour line indicating that there was no need to change the dosing interval. In two episodes (2%), serum creatinine rose transiently by more than 50% of the baseline concentration. Although there was no vestibular toxicity, three of 30 children who underwent pure tone audiometry reported high frequency hearing loss in one ear.Conclusion: OD gentamicin can be used safely and effectively to treat febrile neutropenia in children with cancer. When used for a short period (< 5 days), in children not receiving other nephrotoxic drugs and who have normal serum creatinine, serum gentamicin estimations are unnecessary. [ABSTRACT FROM AUTHOR]- Published
- 1999
35. CORRESPONDENCE.
- Author
-
Alexander, Ian, Crompton, Graham, Ward, Michael J., McKay, Sheila, Addis, G.J., Klein, Max, Hull, Richard, Frank, A.O., Hovenden, J.L., John, T. Jacob, Saha, Vaskar, Howell, David, Barbara, J., Hewitt, Patricia, Hamilton, David, Williams, Michael, Wilmshurst, Peter, and Whitfield, Hugh N.
- Subjects
HEALTH ,GENERAL practitioners ,CHLAMYDIA infection treatment ,ASTHMA - Abstract
Focuses on health related issues. Responsibilities of general practitioners in disabling disorders; Use of doxycycline in the treatment of chlamydial infections; Derivation of intravenous beta-agonist in severe acute asthma.
- Published
- 1988
36. Investigation and management of Clostridium difficile colonisation in a paediatric oncology unit.
- Author
-
Schuller, Ildikó, Saha, Vaskar, Lin Lin, Kingston, Judith, Eden, Tim, Tabaqchali, Soad, Schuller, I, Saha, V, Lin, L, Kingston, J, Eden, T, and Tabaqchali, S
- Abstract
Little is known about Clostridium difficile infection in children with cancer but a presumed outbreak has previously been described. The carriage rate before admission to hospital and morbidity is reported to be high, especially in younger children. The prevalence of C difficile infection on a paediatric oncology ward was monitored from June 1991 to May 1992. Twenty eight (13%) of 214 children were found to be infected. Though the temporal distribution suggested an outbreak, polyacrylamide gel electrophoresis identified several different types. Unlike previous reports, infection appeared to be possibly endogenous or possibly environmental in origin rather than due to cross infection; the morbidity was low and age was not a determinant for infection. The duration of hospital stay and the primary diagnosis were found to be determinants for infections, those with lymphoid malignancies being at the highest risk. The diagnostic category at greatest risk were those most intensively treated, with protracted neutropenia and prolonged antibiotic exposure. Early identification of cases and prompt institution of simple control measures will prevent cross infection. It is therefore important that diarrhoea is not accepted as a normal symptom of cancer chemotherapy and stool specimens are sent for full bacteriological and viral investigation. [ABSTRACT FROM AUTHOR]
- Published
- 1995
- Full Text
- View/download PDF
37. Determinants of symptom interval in childhood cancer.
- Author
-
Saha, Vaskar, Love, Sharon, Eden, Tim, Micallef-Eynaud, Paul, MacKinlay, Gordon, Saha, V, Love, S, Eden, T, Micallef-Eynaud, P, and MacKinlay, G
- Subjects
TUMOR diagnosis ,AGE distribution ,COMPARATIVE studies ,RESEARCH methodology ,MEDICAL cooperation ,PROGNOSIS ,RESEARCH ,SEX distribution ,TIME ,TUMORS ,EVALUATION research ,RETROSPECTIVE studies ,DISEASE complications - Abstract
The duration of symptoms before diagnosis (lag time) was defined for 184 of 236 children diagnosed as having a malignancy at the Royal Hospital for Sick Children, Edinburgh for the time period January 1982 until December 1990. The natural logarithm of the lag time was correlated with age, gender, diagnostic group, white cell count in acute leukaemia, clinical stage of disease in solid tumours, and event free survival. Age was significantly associated with lag time, older children presenting later. In the diagnostic groups, mean lag time ranged from 2.8 weeks in nephroblastoma to 13.3 weeks for brain tumours. Diagnostic group was predictive for lag time after adjustment for age, with for example, a significantly longer lag time for those with brain tumours. However lag time was not predictive of event free survival and it is likely that lag time has other major determinants. When compared with previous studies, there also appears to be a regional variation in lag time for diagnostic groups. It seems likely that this is a reflection of geographical difference in the structure of health systems and is therefore yet another important determinant. [ABSTRACT FROM AUTHOR]
- Published
- 1993
- Full Text
- View/download PDF
38. Gene BRI40, Which is Related to AF1O and AF17, Maps to Chromosome Band 3p25.
- Author
-
Sahin, Feride I., Lillington, Debra M., Meerabux, Joanne, Saha, Vaskar, McCullagh, Paul, Young, Bryan D., Gregorini, Armando, Bocci, Maura, Papa, Stefano, and Menevse, Sevda
- Published
- 1996
- Full Text
- View/download PDF
39. Increased radiosensitivity in a child with T-cell non-Hodgkin's lymphoma.
- Author
-
Attard-Montalto, Simon, Saha, Vaskar, Kingston, Judith, Plowman, Nicholas, Taylor, Malcolm, Arlett, Colin, Bridges, Bryn, and Eden, Osborn
- Published
- 1996
- Full Text
- View/download PDF
40. Anaplastic large cell lymphoma in childhood.
- Author
-
Eden, O. B., D'Angio, Giulio J., Evans, Audrey E., Attard-Montalto, Simon P., Saha, Vaskar, Norton, Andrew J., and Kingston, Judith E.
- Published
- 1993
- Full Text
- View/download PDF
41. An odyssey in search of a cure: the evolution of treatment of childhood acute lymphoblastic leukemia in the United Kingdom.
- Author
-
Saha, Vaskar, Eden, Tim, Saha, V, and Eden, T
- Subjects
ANTINEOPLASTIC agents ,LYMPHOBLASTIC leukemia treatment ,COMPARATIVE studies ,LYMPHOBLASTIC leukemia ,RESEARCH methodology ,MEDICAL cooperation ,RESEARCH ,DISEASE relapse ,EVALUATION research - Abstract
This review charts the evolution of therapy for childhood acute lymphoblastic leukaemia (ALL) in the United Kingdom. The present chemotherapeutic regimen is the result of experience gained from carefully planned randomised cooperative studies carried out during the last two decades. In common with the experience of the West German and American groups, the best results have been in those treated with post remission intensification blocks. With current chemotherapy protocols, almost 70% of children with ALL in U.K. can be cured but there may be a medical cost of such a cure, in terms of both acute and long term toxicity. This was especially true when central nervous system (CNS) therapy with cranial irradiation was used. Therefore present regimens are examining chemotherapeutic options for CNS disease control and the efficacy of additional post remission intensification. Failure of chemotherapy is most often seen in those children with a presenting white cell count of more than 50 x 10(9)/l, very young children and/or the presence of certain chromosomal rearrangements (e.g. t4: 11, t9: 22). At present the optimum therapeutic option for such high risk patients and for the majority of those in second remission, is an allogenic bone marrow transplant if an HLA-matched sibling is available. Modern day therapy is both complicated and costly and will be beyond the resources available for most children with ALL in developing countries. A significant decrease in worldwide mortality due to ALL will only occur if either the disease can be prevented or a simpler cure devised. [ABSTRACT FROM AUTHOR]
- Published
- 1993
- Full Text
- View/download PDF
42. Microbiology, infection control and infection related outcome in pediatric patients in an oncology center in Eastern India: Experience from Tata Medical Center, Kolkata.
- Author
-
Bhattacharyya, Arpita, Krishnan, Shekhar, Saha, Vaskar, Goel, Gaurav, Bhattacharya, Sanjay, and Hmar, Lalawmpuia
- Subjects
MICROBIOLOGY ,INFECTION prevention ,PEDIATRICS ,ONCOLOGY ,PATIENTS ,TUMOR treatment ,ANTIBIOTICS ,ANTIFUNGAL agents ,CANCER treatment ,CANDIDIASIS ,PREVENTION of communicable diseases ,DRUG resistance in microorganisms ,GRAM-negative bacterial diseases ,TUMORS ,SPECIALTY hospitals ,DISEASE incidence ,RETROSPECTIVE studies ,DISEASE complications ,PHARMACODYNAMICS - Abstract
Context: Infection is a major determinant in the outcome of patients with cancer.Aims: The aim was to know the epidemiology and outcome of patients with cancer in a cancer care center in Eastern India.Settings and Design: Retrospective study of pediatric patients in Tata Medical Center, Kolkata, India.Methods: Patients (n = 262) between the age group of 0 and 18 years were reviewed for infections and infection-related outcome (January to December 2013).Statistical Analysis: Modified Wald method was used to determine confidence interval of proportions.Results: Gram-negative bacteria were found to be the most common cause of bloodstream infections (BSIs) (56.4%), followed by Gram-positive cocci (34.5%), and Candida species (9.1%). Carbapenem-resistance was noted among 24% of Gram-negative bacilli (GNB), and extended-spectrum beta-lactamase among 64% of GNBs. A single case of Vibrio cholerae septicemia was also noted. No case of vancomycin-resistant Enterococcus was observed, whereas only two cases of methicillin-resistant Staphylococcus aureus bacteremia (1/3 of all Staphylococcus aureus bacteremia) were detected. Escherichia coli, followed by Klebsiella, Pseudomonas, and Acinetobacter were the predominant organisms detected in BSIs. Among Candida spp. BSIs no resistance to caspofungin, amphotericin B, Voriconazole was noted. Candida tropicalis was the most common isolate, and 1 isolate of Candida glabrata showed dose-dependent sensitivity to fluconazole. Three out of 25 patients died of multi-drug resistant Gram-negative bacteria (12%) in 2013. Seventeen patients had radiological evidence of invasive fungal infections (no mortality was noted).Conclusions: Periodic review of infection-related data, as well as infection control practices, is essential to optimize clinical outcome in patients with pediatric malignancies. [ABSTRACT FROM AUTHOR]- Published
- 2014
- Full Text
- View/download PDF
43. Veno-occlusive disease in patients receiving thiopurines during maintenance therapy for childhood acute lymphoblastic leukaemia.
- Author
-
Stoneham, Sara, Lennard, Lynne, Coen, Pietro, Lilleyman, John, and Saha, Vaskar
- Subjects
VEIN diseases ,THERAPEUTICS ,JUVENILE diseases - Abstract
Summary. The case records of 99 consecutive children with acute lymphoblastic leukaemia who received either 6-thioguanine (6-TG) or 6-mercaptopurine (6-MP) as maintenance therapy for at least 1 year were reviewed for hepatic veno-occlusive disease (VOD). Overall, 12% of those on 6-TG developed VOD (all boys). Isolated persistent thrombocytopenia appeared to be the earliest indicator of incipient VOD. Multivariate analysis identified male sex and 6-TG as risk factors. In all cases, VOD was mild and reversible on withdrawing 6-TG or replacing it with 6-MP. The data implicate a sex-linked polymorphic variation in xenobiotic pathways of thiopurine metabolism in the pathogenesis of VOD. [ABSTRACT FROM AUTHOR]
- Published
- 2003
- Full Text
- View/download PDF
44. Routine blood counts in children with acute lymphoblastic leukaemia after completion of therapy: are they necessary?
- Author
-
Gandhi, Minal, Rao, Kanchana, Chua, Siew, Saha, Vaskar, Lilleyman, John, and Shankar, Ananth
- Subjects
LYMPHOBLASTIC leukemia in children ,DISEASE relapse ,JUVENILE diseases ,LEUKEMIA treatment - Abstract
Summary. Children who have completed treatment for acute lymphoblastic leukaemia (ALL) are commonly followed up for the first 5 years with regular full blood counts (FBCs) to monitor for relapse of disease. There is little evidence to suggest that this practice improves the detection rate of unexpected relapse. Surveillance FBCs, performed on 43 children with relapsed ALL between 1990 and 1999, were analysed. Of the 42 relapses in children off therapy, only two were detected by an abnormal FBC. Routine FBCs in asymptomatic children off therapy lacks specificity in detecting unexpected relapses and maybe safely discontinued. [ABSTRACT FROM AUTHOR]
- Published
- 2003
- Full Text
- View/download PDF
45. AF6 gene on chromosome band 6q27 maps distal to the minimal region of deletion in epithelial ovarian cancer.
- Author
-
Saha, Vaskar, Lillington, Debra M., Shelling, Andrew N., Chaplin, Tracy, Yaspo, Marie-Laure, Ganesan, Trivadi S., and Young, Bryan D.
- Published
- 1995
- Full Text
- View/download PDF
46. The Treatment of Pseudomonas aeruginosa Meningitis Old Regime or Newer Drugs??
- Author
-
Saha, Vaskar, Stansfield, Rosamund, Masterton, Robert, and Eden, Tim
- Published
- 1993
- Full Text
- View/download PDF
47. Late-Onset Hemorrhagic Cystitis Following Bone Marrow Transplantation: A Case Report.
- Author
-
Goddard, Andrea G. and Saha, Vaskar
- Published
- 1997
- Full Text
- View/download PDF
48. Long-Term Prednisolone Therapy in Children with Idiopathic Pulmonary Hemosiderosis.
- Author
-
Saha, Vaskar, Ravikumar, Edwin, Khandliri, Uma, Date, Anand, and Raghupathy, P.
- Published
- 1993
- Full Text
- View/download PDF
49. A triple-probe FISH screening strategy for risk-stratified therapy of acute lymphoblastic leukaemia in low-resource settings.
- Author
-
Parihar, Mayur, Singh, Manish K., Islam, Rubina, Saha, Debparna, Mishra, Deepak Kumar, Saha, Vaskar, and Krishnan, Shekhar
- Published
- 2018
- Full Text
- View/download PDF
50. Acute lymphoblastic leukaemia cells produce large extracellular vesicles containing organelles and an active cytoskeleton.
- Author
-
Johnson, Suzanne M., Dempsey, Clare, Parker, Catriona, Mironov, Aleksandr, Bradley, Helen, and Saha, Vaskar
- Subjects
LYMPHOBLASTIC leukemia ,VESICLES (Cytology) ,LEUKEMIA ,EXTRACELLULAR enzymes ,ORGANELLES ,CYTOSKELETON - Abstract
Extracellular vesicles have been described in non-paracrine cellular interactions in cancer. We report a similar phenomenon in B-cell precursor (BCP) acute lymphoblastic leukaemia (ALL). Using advanced microscopy and high throughput screening, we further characterise a subset of large vesicles (LEVs) identified in cell lines, murine models of human BCP-ALL and clinical samples. Primary ALL blasts and cell lines released heterogeneous anucleate vesicles <6 micron into extracellular fluids. Larger LEVs were enclosed in continuous membranes, contained intact organelles and demonstrated an organised cytoskeleton. An excess of circulating CD19-positive LEVs were observed in diagnostic samples and isolated from mice engrafted with BCP-ALL primary cells. LEVs exhibited dynamic shape changein vitroand were internalised by other leukaemic cell lines leading to phenotypic transformation analogous to the cell of origin. In patient-derived xenografts, LEVs were released by primary ALL cells into extracellular spaces and internalised by murine mesenchymal cellsin vivo. Collectively these data highlight the heterogeneity but accessibility of LEVs in clinical samples and their potential to provide a unique insight into the biology of the cell of origin and to their development as novel biomarkers to aid diagnosis and improve therapeutic outcomes. [ABSTRACT FROM PUBLISHER]
- Published
- 2017
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.